outperform
reason report
great last year lower mp stock
bottom line downgrad market perform
outperform base view compani clinic stage
pipelin fairli valu visibl addit near-term
sourc upsid limit bullish base
thesi would abl overcom technic challeng
regard lead gene therapi product lentiglobin transfusion-
depend beta-thalassemia tdt sever sickl cell diseas scd
compani car-t product underappreci
investor link share appreci vs nbi
sinc initi coverag februari
manag execut well term advanc pipelin
today downgrad share market perform
think market cap pipelin fairli valu
look execut year visibl addit value-cr
catalyst alreadi reflect stock limit view
investor understand enthus recent uptick
activ sector said trade ev
revenu forecast think share includ signific
premium think may ultim acquir
difficult predict acquisit happen near term
updat pt includ acquisit premium
look execut year plan
complet starbeam trial lenti-d ccald plan
regulatori submiss submit regulatori file europ
lentiglobin tdt forecast us regulatori file
latter half assum year follow-up
trial provid updat scd studi year-end
apheresis-bas stem cell harvest like initi pivot trial
assum regulatori file multipl myeloma
celg op guid biolog licens applic bla submiss
launch phase trial line patient
expect initi late work undisclos
earli stage pipelin asset oncolog rare diseas visibl
limit think investor attribut much addit valu
proof-of-concept poc clinic data gener
think like occur beyond
model account high probability-of-success
clinic stage pipelin follow recent posit updat
link rais probability-of-success po assumpt
lentiglobin scd po assumpt tdt
compani inform leerink partner llc research
revenu million
dcf sop analysi discount
rate termin growth rate
pleas refer page import disclosur price chart analyst certif
genotyp pos-assumpt
anti-bcma franchis pos-
assumpt ccald updat probability-adjust ww
revenu estim includ
base un-adjust total peak sale estim
stock trade similar rel absolut valuat juno
kite acquisit price market cap ev
alreadi trade upper end rang juno
mp kite rel takeout valuat peak sale
view said gener signific product sale
two year later kite one year later juno
potenti rais hurdl lower valuat acquisit
rel comp celg justifi acquisit juno
probability-adjust peak sale estim plu
juno pipelin correspond ev/ multipl
take account portion busi alreadi own make
similar assumpt yescarta sale kite mp paid
ev/sal current trade ev revenu
forecast appli juno kite takeout multipl revenu
forecast result would indic upsid downsid respect
straight dcf valuat result pt wacc
assumpt tg current pt assum wacc
probabl acquisit cost capit also
updat estim reflect recent financ updat
rate share market perform one lead gene therapi
compani special ex-vivo gene therapi rare genet diseas oncolog
gene therapi tremend promis rel new treatment modal also pose
technic clinic regulatori commerci challeng seem overcom initi
technic challeng lead product candid lentiglobin develop one-
time treatment transfusion-depend beta-thalassemia tdt sever sickl cell diseas
scd compani bcma-target car-t product licens celgen
gener impress proof-of-concept clinic data multipl myeloma current valuat
think pipelin fairli valu look execut year visibl
value-cr catalyst alreadi reflect stock limit view
develop addit product candid repres signific sourc upsid longer
term think investor assign addl valu proof-of-concept clinic data
gener think like occur beyond may ultim
acquir difficult predict acquisit happen near term
one-year price target per share pt base assign
probability-of-success po lenti-d ccald well po lentiglobin beta-
thalassemia major account probabl respect sickl cell diseas
multipl myeloma car-t valuat base discount cash
flow sum-of-the-part analysi use discount rate rather typic use
development-stag sinc includ premium valuat
use termin growth rate
face signific clinic regulatori risk sinc product candid current
earli stage clinic preclin develop like mani development stage biopharma
compani also face manufactur competit commerci regulatori safeti risk
well risk intellectu properti also face financ risk dilut current
sharehold sinc dont believ compani achiev cash-flow break-even base
current cash balanc may acquir premium add addit product candid
pipelin current reflect stock valuat
net year
initi
initi
 mm
reseach licens fee
licens revenu
chang fair valu conting consider
total incom expens
bs cf mm
sec file leerink partner estim
chang
oper
invest
financ
sec file leerink partner estim
year
